Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Westchester Capital Management LLC

Westchester Capital Management LLC reduced its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 83.0% in the 4th quarter, HoldingsChannel reports. The firm owned 189,844 shares of the health services provider’s stock after selling 928,958 shares during the quarter. Amedisys makes up 0.9% of Westchester Capital Management LLC’s portfolio, making the stock its 23rd largest position. Westchester Capital Management LLC’s holdings in Amedisys were worth $17,236,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. increased its position in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC purchased a new position in shares of Amedisys during the fourth quarter valued at approximately $38,000. Versant Capital Management Inc boosted its position in Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after acquiring an additional 183 shares during the last quarter. Vestcor Inc purchased a new stake in Amedisys in the 4th quarter worth approximately $73,000. Finally, Venturi Wealth Management LLC grew its stake in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock worth $89,000 after acquiring an additional 779 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Stephens reiterated an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Amedisys has a consensus rating of “Hold” and a consensus price target of $100.75.

Amedisys Price Performance

Shares of AMED stock opened at $94.27 on Friday. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.09 billion, a PE ratio of 37.41, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89. The firm has a fifty day simple moving average of $92.17 and a 200-day simple moving average of $91.83.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $594.78 million for the quarter, compared to analysts’ expectations of $597.43 million. Equities research analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.